Shin Nippon Biomedical Laboratories Overview
- Year Founded
-
1957
- Status
-
Public
- Employees
-
1,341
- Stock Symbol
-
2395
- Investments
-
15
- Share Price
-
$8.88
- (As of Thursday Closing)
Shin Nippon Biomedical Laboratories General Information
Description
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment.
Contact Information
Website
snbl.comCorporate Office
- 2438 Miyanoura-cho
- Kagoshima, 891-1394
- Japan
Corporate Office
- 2438 Miyanoura-cho
- Kagoshima, 891-1394
- Japan
Shin Nippon Biomedical Laboratories Stock Performance
As of 24-Apr-2025, Shin Nippon Biomedical Laboratories’s stock price is $8.88. Its current market cap is $370M with 41.6M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $8.88 | $8.86 | $6.66 - $12.43 | $370M | 41.6M | 338K | $0.78 |
Shin Nippon Biomedical Laboratories Financials Summary
As of 31-Dec-2024, Shin Nippon Biomedical Laboratories has a trailing 12-month revenue of $203M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Mar-2024 | FY 2023 31-Mar-2023 | FY 2022 31-Mar-2022 |
|---|---|---|---|---|
| EV | 609,886 | 514,751 | 920,105 | 609,535 |
| Revenue | 202,717 | 183,061 | 185,334 | 157,984 |
| EBITDA | 60,867 | 69,638 | 84,376 | |
| Net Income | 32,633 | 38,281 | 44,763 | 63,445 |
| Total Assets | 619,604 | 504,145 | 429,597 | 322,108 |
| Total Debt | 217,081 | 173,022 | 140,797 | 74,875 |
Shin Nippon Biomedical Laboratories Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Shin Nippon Biomedical Laboratories Comparisons
Industry
Financing
Details
Shin Nippon Biomedical Laboratories Competitors (26)
One of Shin Nippon Biomedical Laboratories’s 26 competitors is Parexel International, a Private Equity-Backed company based in Durham, NC.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Parexel International | Private Equity-Backed | Durham, NC | ||||
| Charles River Laboratories International | Formerly PE-Backed | Wilmington, MA | ||||
| Covance | Formerly PE-Backed | Princeton, NJ | ||||
| Vimta Labs | Corporation | Hyderabad, India | ||||
| Crown Bioscience | Formerly VC-backed | San Diego, CA |
Shin Nippon Biomedical Laboratories Patents
Shin Nippon Biomedical Laboratories Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2025041218-A | Biomarkers including limch1 | Pending | 13-Sep-2023 | ||
| JP-2024082681-A | Medication determination device and determination program | Pending | 08-Dec-2022 | ||
| AU-2023327330-A1 | Administration device | Pending | 17-Aug-2022 | ||
| EP-4470561-A1 | Adjuvant composition and vaccine composition | Pending | 25-Jan-2022 | ||
| US-20230046122-A1 | Urine scattering prevention device | Pending | 27-Jan-2020 | E03D13/005 |
Shin Nippon Biomedical Laboratories Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Shin Nippon Biomedical Laboratories Investments & Acquisitions (15)
Shin Nippon Biomedical Laboratories’s most recent deal was a Joint Venture with Distribution of Blood Collection Device (Shin Nippon Biomedical Laboratories / Tasso). The deal was made on 27-Mar-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Distribution of Blood Collection Device (Shin Nippon Biomedical Laboratories / Tasso) | 27-Mar-2025 | Joint Venture | Distributors/Wholesale | ||
| Biomy | 18-Jul-2024 | Corporate | Decision/Risk Analysis | ||
| Satsuma Pharmaceuticals | 08-Jun-2023 | Merger/Acquisition | Pharmaceuticals | ||
| Biomy | 23-Aug-2022 | Corporate | Decision/Risk Analysis | ||
| Ina Research | 13-Jul-2022 | Merger/Acquisition | Laboratory Services (Healthcare) |
Shin Nippon Biomedical Laboratories ESG
Risk Overview
Risk Rating
Updated November, 28, 2024
18.76 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,109
Rank
Percentile
Pharmaceuticals
Industry
of 861
Rank
Percentile
Laboratory Equipment and Services
Subindustry
of 60
Rank
Percentile
Shin Nippon Biomedical Laboratories Exits (3)
Shin Nippon Biomedical Laboratories’s most recent exit was on 02-Feb-2015 from WaVe Life Sciences. The exit was categorized as with 3 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| WaVe Life Sciences | 02-Feb-2015 | Completed |
|
||
| Agrivida | 09-Nov-2006 | Completed |
|
||
| WaVe Life Sciences | Corporate | Completed |
Shin Nippon Biomedical Laboratories Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Gemseki | Tokyo, Japan | 2017 | |
| Satsuma Pharmaceuticals | Durham, NC | 2016 | |
| Ina Research | Ina, Japan | 1974 |
Shin Nippon Biomedical Laboratories FAQs
-
When was Shin Nippon Biomedical Laboratories founded?
Shin Nippon Biomedical Laboratories was founded in 1957.
-
Where is Shin Nippon Biomedical Laboratories headquartered?
Shin Nippon Biomedical Laboratories is headquartered in Kagoshima, Japan.
-
What is the size of Shin Nippon Biomedical Laboratories?
Shin Nippon Biomedical Laboratories has 1,341 total employees.
-
What industry is Shin Nippon Biomedical Laboratories in?
Shin Nippon Biomedical Laboratories’s primary industry is Drug Discovery.
-
Is Shin Nippon Biomedical Laboratories a private or public company?
Shin Nippon Biomedical Laboratories is a Public company.
-
What is Shin Nippon Biomedical Laboratories’s stock symbol?
The ticker symbol for Shin Nippon Biomedical Laboratories is 2395.
-
What is the current stock price of Shin Nippon Biomedical Laboratories?
As of 24-Apr-2025 the stock price of Shin Nippon Biomedical Laboratories is $8.88.
-
What is the current market cap of Shin Nippon Biomedical Laboratories?
The current market capitalization of Shin Nippon Biomedical Laboratories is $370M.
-
What is Shin Nippon Biomedical Laboratories’s current revenue?
The trailing twelve month revenue for Shin Nippon Biomedical Laboratories is $203M.
-
Who are Shin Nippon Biomedical Laboratories’s competitors?
Parexel International, Charles River Laboratories International, Covance, Vimta Labs, and Crown Bioscience are some of the 26 competitors of Shin Nippon Biomedical Laboratories.
-
What is Shin Nippon Biomedical Laboratories’s annual earnings per share (EPS)?
Shin Nippon Biomedical Laboratories’s EPS for 12 months was $0.78.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
